Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) correlated with anti-Spike (S) IgG d42 titers (Spearman r = 0.865, p < 0.0001), and an anti-S IgG d42 level ≥3100 UA/mL...

Descripción completa

Detalles Bibliográficos
Autores principales: Malard, Florent, Gaugler, Béatrice, Gozlan, Joel, Bouquet, Lucie, Fofana, Djeneba, Siblany, Lama, Eshagh, Deborah, Adotevi, Olivier, Laheurte, Caroline, Ricard, Laure, Dulery, Rémy, Stocker, Nicolas, van de Wyngaert, Zoe, Genthon, Alexis, Banet, Anne, Memoli, Mara, Ikhlef, Souhila, Sestilli, Simona, Vekhof, Anne, Brissot, Eolia, Marjanovic, Zora, Chantran, Yannick, Cuervo, Nancy, Ballot, Eric, Morand-Joubert, Laurence, Mohty, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353615/
https://www.ncbi.nlm.nih.gov/pubmed/34376633
http://dx.doi.org/10.1038/s41408-021-00534-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353615/
https://www.ncbi.nlm.nih.gov/pubmed/34376633
http://dx.doi.org/10.1038/s41408-021-00534-z

Ejemplares similares